Alto Neuroscience (ANRO) said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo.
"Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker," Alto Neuroscience said.
ALTO-100 is also being evaluated as an adjunctive treatment in a phase 2b study for bipolar depression, the company said.
Alto expects its current cash position to fund planned operations into 2027 and through multiple upcoming clinical readouts.
Shares of the company plunged 60% in after-hours activity on Tuesday.
Price: 5.82, Change: -8.71, Percent Change: -59.94
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。